Dexcom to Add Board Directors in Elliott Agreement
Dexcom will add two directors and revamp its board committee in a deal with Elliott. The medical device maker aims to boost margins and operational expertise.
Xurve View
洞察:
Xurve View
DEXCOM INC will appoint two independent directors and restructure a key board committee following an agreement with activist investor Elliott Investment Management. Shares rose 6% in after-hours trading. The board currently lacks medtech and operations expertise, an area the medical device maker is addressing as it positions for future growth.
